

Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Medication Precertification Request

Page 1 of 1

 Aetna Precertification Notification

 Phone:
 1-866-752-7021

 FAX:
 1-888-267-3277

 For Medicare Advantage Part B:

 Phone:
 1-866-503-0857

 FAX:
 1-844-268-7263

(All fields must be Please indicate: Start of treatment: Start date	completed and legible for	r precertification review.)		FAX: 1-84	44-268-7263
Continuation of therapy, Date		/ /			
Precertification Requested By:		Phone:		Fax:	
A. PATIENT INFORMATION					
First Name:	Last Name:			DOB:	
Address:		City:		State:	ZIP:
Home Phone: Work Phone:		Cell Phone:		Email:	
Patient Current Weight: lbs_or kgs	Patient Height:	_inches orcms	Allergi	es:	
B. INSURANCE INFORMATION					
Aetna Member ID #: Does patient have		-			
		Carrier Name:			
Insured:	Insured:				
Medicare: Yes No If yes, provide ID #:	N	No 🗌 Medicaid: 🗌 Yes	If yes, prov	/ide ID #:	
C. PRESCRIBER INFORMATION					
First Name:	Last Name:	(Check Or		-	D.O N.P P.A
Address:		City:		State:	ZIP:
Phone: Fax:	St Lic #:	NPI #:	DEA #:	-1	UPIN:
Provider Email:	Office Contact Name	e:		Phone:	
Specialty (Check one): Oncologist Other:					
D. DISPENSING PROVIDER/ADMINISTRATION INFO	ORMATION				
Place of Administration:		Dispensing Provider	r/Pharmac	y: Patient Se	elected choice
Self-administered Physician's Office		Physician's Office			
Outpatient Infusion Center Phone:		Specialty Pharmacy Other			
Center Name:		Name:			
Home Infusion Center Phone:		Address:			
Agency Name:		Phone: Fax:			
Administration code(s) (CPT):			TIN: PIN:		
				1	
E. PRODUCT INFORMATION	waanthami (racambin	ant) nuun)			
Request is for: Rylaze (asparaginase erwinia chr Dose:	ysantnenn (recombina	Frequency:			
F. DIAGNOSIS INFORMATION - Please indicate prima	ary ICD code and speci		ole.		
Primary ICD Code:	Secondary ICD Co	ode:	Other	ICD Code:	
G. CLINICAL INFORMATION - Required clinical inform	mation must be complet	ted in its <u>entirety</u> for all prec	ertification	requests.	
☐ Yes ☐ No Does the patient have a diagnosis of a					
→ Please explain: □ acute lymphoblast		ymphoblastic lymphoma (L	BL)		
For Initiation Requests (clinical documentation requ					
☐ Yes ☐ No Has the patient developed hypersensit ☐ Yes ☐ No Will the requested drug used in conjunt	-		argase)?		
	_	chemotherapy?			
For Continuation Requests (clinical documentation Yes No Is there evidence of unacceptable toxi		sion while on the current rea	nimen?		
H. ACKNOWLEDGEMENT					
Request Completed By (Signature Required):				Date	
Any person who knowingly files a request for authorizany insurance company by providing materially false in					

any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fr insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.